title: The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
abstract: Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.
authors.affiliation: Department of Pharmacy, Unit of PharmacoEpidemiology and Pharmacoeconomics (PE2), University of Groningen, Groningen, The Netherlands.
authors.forename: Didik
authors.initials: D
authors.lastname: Setiawan
authors.forename: Jos
authors.initials: J
authors.lastname: Luttjeboer
authors.forename: Tjalke Arend
authors.initials: TA
authors.lastname: Westra
authors.forename: Jan C
authors.initials: JC
authors.lastname: Wilschut
authors.forename: Auliya A
authors.initials: AA
authors.lastname: Suwantika
authors.forename: Toos
authors.initials: T
authors.lastname: Daemen
authors.forename: Jarir
authors.initials: J
authors.lastname: Atthobari
authors.forename: Bob
authors.initials: B
authors.lastname: Wilffert
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods; D009426:Netherlands; D030361:Papillomavirus Infections / Q000150:complications / Q000191:economics* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000191:economics* / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics* / Q000706:statistics & numerical data
chemical_list: D053918:Papillomavirus Vaccines
keywords: HPV vaccination; The Netherlands; cervical cancer; cervical cancer screening; cost–effectiveness